|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics. 2012.CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Feig C, Gopinathan A, Neesse A, Chan DS,
Cook N and Tuveson DA: The pancreas cancer microenvironment. Clin
Cancer Res. 18:4266–4276. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Amakye D, Jagani Z and Dorsch M:
Unraveling the therapeutic potential of the Hedgehog pathway in
cancer. Nat Med. 19:1410–1422. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Özdemir BC, Pentcheva-Hoang T, Carstens
JL, et al: Depletion of carcinoma-associated fibroblasts and
fibrosis induces immunosuppression and accelerates pancreas cancer
with reduced survival. Cancer Cell. 25:719–734. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Provenzano PP, Cuevas C, Chang AE, Goel
VK, Von Hoff DD and Hingorani SR: Enzymatic targeting of the stroma
ablates physical barriers to treatment of pancreatic ductal
adenocarcinoma. Cancer Cell. 21:418–429. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Koong AC, Mehta VK, Le QT, et al:
Pancreatic tumors show high levels of hypoxia. Int J Radiat Oncol
Biol Phys. 48:919–922. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Campbell PJ, Yachida S, Mudie LJ, et al:
The patterns and dynamics of genomic instability in metastatic
pancreatic cancer. Nature. 467:1109–1113. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yachida S, Jones S, Bozic I, et al:
Distant metastasis occurs late during the genetic evolution of
pancreatic cancer. Nature. 467:1114–1117. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yamada S, Fuchs BC, Fujii T, et al:
Epithelial-to-mesenchymal transition predicts prognosis of
pancreatic cancer. Surgery. 154:946–954. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chan N, Milosevic M and Bristow RG: Tumor
hypoxia, DNA repair and prostate cancer progression: new targets
and new therapies. Future Oncol. 3:329–341. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kroemer G and Pouyssegur J: Tumor cell
metabolism: cancer's Achilles' heel. Cancer Cell. 13:472–482. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Vander Heiden MG, Cantley LC and Thompson
CB: Understanding the Warburg effect: the metabolic requirements of
cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Christofk HR, Vander Heiden MG, Harris MH,
et al: The M2 splice isoform of pyruvate kinase is important for
cancer metabolism and tumour growth. Nature. 452:230–233. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wolf A, Agnihotri S, Micallef J, et al:
Hexokinase 2 is a key mediator of aerobic glycolysis and promotes
tumor growth in human glioblastoma multiforme. J Exp Med.
208:313–326. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mitsunaga S, Hasebe T, Iwasaki M,
Kinoshita T, Ochiai A and Shimizu N: Important prognostic
histological parameters for patients with invasive ductal carcinoma
of the pancreas. Cancer Sci. 96:858–865. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mitsunaga S, Hasebe T, Kinoshita T, et al:
Detail histologic analysis of nerve plexus invasion in invasive
ductal carcinoma of the pancreas and its prognostic impact. Am J
Surg Pathol. 31:1636–1644. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Takahashi H, Ohigashi H, Ishikawa O, et
al: Perineural invasion and lymph node involvement as indicators of
surgical outcome and pattern of recurrence in the setting of
preoperative gemcitabine-based chemoradiation therapy for
resectable pancreatic cancer. Ann Surg. 255:95–102. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nakata B, Fukunaga S, Noda E, Amano R,
Yamada N and Hirakawa K: Chemokine receptor CCR7 expression
correlates with lymph node metastasis in pancreatic cancer.
Oncology. 74:69–75. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Komoto M, Nakata B, Amano R, et al: HER2
overexpression correlates with survival after curative resection of
pancreatic cancer. Cancer Sci. 100:1243–1247. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Javle MM, Gibbs JF, Iwata KK, et al:
Epithelial-mesenchymal transition (EMT) and activated extracellular
signal-regulated kinase (p-Erk) in surgically resected pancreatic
cancer. Ann Surg Oncol. 14:3527–3533. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Guillaumond F, Iovanna JL and Vasseur S:
Pancreatic tumor cell metabolism: focus on glycolysis and its
connected metabolic pathways. Arch Biochem Biophys. 545:69–73.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Semenza GL: Defining the role of
hypoxia-inducible factor 1 in cancer biology and therapeutics.
Oncogene. 29:625–634. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Semenza GL: HIF-1: upstream and downstream
of cancer metabolism. Curr Opin Genet Dev. 20:51–56. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Peitzsch C, Perrin R, Hill RP, Dubrovska A
and Kurth I: Hypoxia as a biomarker for radioresistant cancer stem
cells. Int J Radiat Biol. 90:636–652. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Medina RA and Owen GI: Glucose
transporters: expression, regulation and cancer. Biol Res. 35:9–26.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Airley RE and Mobasheri A: Hypoxic
regulation of glucose transport, anaerobic metabolism and
angiogenesis in cancer: novel pathways and targets for anticancer
therapeutics. Chemotherapy. 53:233–256. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Haber RS, Rathan A, Weiser KR, et al:
GLUT1 glucose transporter expression in colorectal carcinoma: a
marker for poor prognosis. Cancer. 83:34–40. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rempel A, Mathupala SP and Perdersen PL:
Glucose catabolism in cancer cells: regulation of the Type II
hexokinase promoter by glucose and cyclic AMP. FEBS Lett.
385:233–237. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mathupala SP, Rempel A and Pedersen PL:
Aberrant glycolytic metabolism of cancer cells: a remarkable
coordination of genetic, transcriptional, post-translational and
mutational events that lead to a critical role for type II
hexokinase. J Bioenerg Biomembr. 29:339–343. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Di Chiro G, DeLaPaz RL, Brooks RA, et al:
Glucose utilization of cerebral gliomas measured by
[18F] fluorodeoxyglucose and positron emission
tomography. Neurology. 32:1323–1329. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pedersen PL: Warburg, me and Hexokinase 2:
Multiple discoveries of key molecular events underlying one of
cancers' most common phenotypes, the ‘Warburg Effect’, i.e.,
elevated glycolysis in the presence of oxygen. J Bioenerg Biomembr.
39:211–222. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mazurek S: Pyruvate kinase type M2: a key
regulator within the tumour metabolome and a tool for metabolic
profiling of tumours. Ernst Schering Found Symp Proc. 43:969–980.
2007.
|
|
33
|
Bardeesy N and DePinho RA: Pancreatic
cancer biology and genetics. Nat Rev Cancer. 2:897–909. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Manning BD and Cantley LC: AKT/PKB
signaling: navigating downstream. Cell. 129:1261–1274. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ramanathan A, Wang C and Schreiber SL:
Perturbational profiling of a cell-line model of tumorigenesis by
using metabolic measurements. Proc Natl Acad Sci USA.
102:5992–5997. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Feron O: Pyruvate into lactate and back:
from the Warburg effect to symbiotic energy fuel exchange in cancer
cells. Radiother Oncol. 92:329–333. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lyshchik A, Higashi T, Hara T, et al:
Expression of glucose transporter-1, hexokinase-II, proliferating
cell nuclear antigen and survival of patients with pancreatic
cancer. Cancer Invest. 25:154–162. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Mamede M, Higashi T, Kitaichi M, et al:
[18F] FDG uptake and PCNA, Glut-1 and Hexokinase-II
expressions in cancers and inflammatory lesions of the lung.
Neoplasia. 7:369–379. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sato-Tadano A, Suzuki T, Amari M, et al:
Hexokinase II in breast carcinoma: a potent prognostic factor
associated with hypoxia-inducible factor-1α and Ki-67. Cancer Sci.
104:1380–1388. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li J, Yang Z, Zou Q, et al: PKM2 and ACVR
1C are prognostic markers for poor prognosis of gallbladder cancer.
Clin Transl Oncol. 16:200–207. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lim JY, Yoon SO, Seol SY, et al:
Overexpression of the M2 isoform of pyruvate kinase is an adverse
prognostic factor for signet ring cell gastric cancer. World J
Gastroenterol. 18:4037–4043. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Luo W and Semenza GL: Pyruvate kinase M2
regulates glucose metabolism by functioning as a coactivator for
hypoxia-inducible factor 1 in cancer cells. Oncotarget. 2:551–556.
2011.PubMed/NCBI
|
